UBS Group
DFTX

UBS Group’s Definium Therapeutics DFTX Stock Holding History

UBS Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.34M Sell
493,977
-189,825
-28% -$3.22M ﹤0.01% 3436
2025
Q4 		$9.16M Buy
683,802
+131,993
+24% +$1.63M ﹤0.01% 3385
2025
Q3 		$6.51M Buy
551,809
+37,364
+7% +$348K ﹤0.01% 3768
2025
Q2 		$3.34M Buy
514,445
+406,419
+376% +$2.67M ﹤0.01% 4290
2025
Q1 		$632K Sell
108,026
-6,412
-6% -$45.9K ﹤0.01% 5676
2024
Q4 		$796K Sell
114,438
-13,860
-11% -$95.4K ﹤0.01% 5485
2024
Q3 		$730K Buy
128,298
+71,810
+127% +$499K ﹤0.01% 4924
2024
Q2 		$407K Buy
56,488
+32,104
+132% +$281K ﹤0.01% 5166
2024
Q1 		$229K Buy
24,384
+23,981
+5,951% +$137K ﹤0.01% 5761
2023
Q4 		$1.48K Sell
403
-4,111
-91% -$12.4K ﹤0.01% 8294
2023
Q3 		$14.1K Buy
4,514
+3,762
+500% +$15.5K ﹤0.01% 6966
2023
Q2 		$2.68K Sell
752
-9,050
-92% -$31.2K ﹤0.01% 7714
2023
Q1 		$31.1K Sell
9,802
-5,734
-37% -$19.1K ﹤0.01% 6774
2022
Q4 		$34.2K Sell
15,536
-6,711
-30% -$18.6K ﹤0.01% 7108
2022
Q3 		$78K Buy
22,247
+20,451
+1,139% +$196K ﹤0.01% 5932
2022
Q2 		$17K Buy
1,796
+374
+26% +$4.73K ﹤0.01% 7101
2022
Q1 		$24K Sell
1,422
-5,700
-80% -$98.9K ﹤0.01% 7245
2021
Q4 		$147K Buy
7,122
+7,052
+10,074% +$225K ﹤0.01% 5950
2021
Q3 		$2K Buy
70
+53
+312% +$2.29K ﹤0.01% 8966
2021
Q2 		$1K Buy
+17
New +$892 ﹤0.01% 9164

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group's DFTX Position: Q1 2026 in Review

UBS Group reduced its Definium Therapeutics (DFTX) stake by 28% in Q1 2026, selling an estimated $3.22M and leaving 493,977 shares worth $9.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3436.

UBS Group first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • UBS Group held 493,977 shares of Definium Therapeutics worth $9.34M as of Q1 2026.
  • UBS Group sold 189,825 Definium Therapeutics shares in Q1 2026, an estimated $3.22M.
  • Definium Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3436 holding.
  • UBS Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.